Bank of America’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-7,500
Closed -$4.22M 8167
2025
Q3
$4.22M Hold
7,500
﹤0.01% 4178
2025
Q2
$3.94M Sell
7,500
-9,700
-56% -$5.41M ﹤0.01% 4139
2025
Q1
$10.9M Sell
17,200
-23,600
-58% -$16.2M ﹤0.01% 3047
2024
Q4
$29.1M Buy
40,800
+2,300
+6% +$1.93M ﹤0.01% 1962
2024
Q3
$40.5M Sell
38,500
-27,100
-41% -$30.2M ﹤0.01% 1750
2024
Q2
$68.9M Buy
65,600
+39,300
+149% +$38.1M 0.01% 1237
2024
Q1
$25.3M Sell
26,300
-2,700
-9% -$2.57M ﹤0.01% 2051
2023
Q4
$25.5M Sell
29,000
-7,200
-20% -$5.93M ﹤0.01% 1913
2023
Q3
$29.8M Buy
36,200
+4,700
+15% +$3.69M ﹤0.01% 1662
2023
Q2
$22.6M Sell
31,500
-26,000
-45% -$20M ﹤0.01% 1906
2023
Q1
$47.2M Buy
57,500
+23,500
+69% +$17.7M ﹤0.01% 1411
2022
Q4
$24.5M Sell
34,000
-14,000
-29% -$10.3M ﹤0.01% 1843
2022
Q3
$33.1M Buy
48,000
+27,500
+134% +$17.3M ﹤0.01% 1580
2022
Q2
$12.1M Hold
20,500
﹤0.01% 2492
2022
Q1
$14.3M Sell
20,500
-34,500
-63% -$21.8M ﹤0.01% 2493
2021
Q4
$34.7M Buy
55,000
+50,000
+1,000% +$30.7M ﹤0.01% 1708
2021
Q3
$3.03M Sell
5,000
-40,400
-89% -$25.1M ﹤0.01% 4055
2021
Q2
$25.4M Sell
45,400
-52,000
-53% -$26.3M ﹤0.01% 1925
2021
Q1
$46.1M Buy
97,400
+65,000
+201% +$31.6M 0.01% 1359
2020
Q4
$15.7M Buy
32,400
+27,400
+548% +$14.8M ﹤0.01% 2115
2020
Q3
$2.8M Hold
5,000
﹤0.01% 3415
2020
Q2
$3.12M Sell
5,000
-10,000
-67% -$5.68M ﹤0.01% 3274
2020
Q1
$7.32M Sell
15,000
-8,200
-35% -$3.38M ﹤0.01% 2316
2019
Q4
$8.71M Buy
23,200
+16,000
+222% +$5.38M ﹤0.01% 2686
2019
Q3
$2M Hold
7,200
﹤0.01% 4054
2019
Q2
$2.25M Sell
7,200
-12,100
-63% -$4.03M ﹤0.01% 3957
2019
Q1
$7.92M Sell
19,300
-9,600
-33% -$3.95M ﹤0.01% 2711
2018
Q4
$10.8M Buy
28,900
+7,200
+33% +$2.64M ﹤0.01% 2226
2018
Q3
$8.77M Sell
21,700
-8,400
-28% -$3.2M ﹤0.01% 2614
2018
Q2
$10.4M Sell
30,100
-43,600
-59% -$13.6M ﹤0.01% 2418
2018
Q1
$25.4M Buy
73,700
+68,100
+1,216% +$23.7M ﹤0.01% 1578
2017
Q4
$2.1M Sell
5,600
-6,600
-54% -$2.67M ﹤0.01% 3897
2017
Q3
$5.46M Buy
+12,200
New +$5.81M ﹤0.01% 3106
2017
Q2
Sell
-46,100
Closed -$17.9M 7128
2017
Q1
$17.9M Buy
46,100
+42,900
+1,341% +$15.9M ﹤0.01% 1855
2016
Q4
$1.18M Sell
3,200
-4,500
-58% -$1.71M ﹤0.01% 4210
2016
Q3
$3.1M Hold
7,700
﹤0.01% 3273
2016
Q2
$2.69M Hold
7,700
﹤0.01% 3385
2016
Q1
$2.77M Hold
7,700
﹤0.01% 3292
2015
Q4
$4.18M Hold
7,700
﹤0.01% 3128
2015
Q3
$3.58M Buy
7,700
+4,500
+141% +$2.42M ﹤0.01% 3209
2015
Q2
$1.63M Buy
+3,200
New +$1.56M ﹤0.01% 3668
2015
Q1
Sell
-38,900
Closed -$16M 7459
2014
Q4
$16M Buy
38,900
+3,300
+9% +$1.3M 0.01% 1553
2014
Q3
$12.8M Buy
35,600
+12,700
+55% +$4.26M ﹤0.01% 1751
2014
Q2
$6.47M Buy
22,900
+12,600
+122% +$3.73M ﹤0.01% 2311
2014
Q1
$3.09M Buy
10,300
+6,000
+140% +$1.85M ﹤0.01% 2817
2013
Q4
$1.18M Sell
4,300
-2,400
-36% -$690K ﹤0.01% 3884
2013
Q3
$2.1M Sell
6,700
-2,400
-26% -$631K ﹤0.01% 3232
2013
Q2
$2.05M Buy
+9,100
New +$2.12M ﹤0.01% 3186

Other funds holding REGN

Bank of America's REGN Position: Q1 2026 in Review

Bank of America increased its Regeneron Pharmaceuticals (REGN) stake by 2.8% in Q1 2026, buying an estimated $24.6M and bringing the position to 1,189,584 shares worth $919M. The position accounts for 0.07% of the portfolio, ranked #263.

Bank of America first reported a position in REGN in Q2 2013 and has held it in 52 quarters since. The position peaked at $1.04B in Q3 2024. 1,396 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Bank of America held 1,189,584 shares of Regeneron Pharmaceuticals worth $919M as of Q1 2026.
  • Bank of America bought 32,158 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $24.6M.
  • Regeneron Pharmaceuticals made up 0.07% of Bank of America's portfolio in Q1 2026, its #263 holding.
  • Bank of America first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Bank of America's Regeneron Pharmaceuticals position peaked at $1.04B in Q3 2024.
  • 1,396 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.